Protalix Biotherapeutics Inc (PLX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $255.49M
Last updated: Nov 17, 2026 at 4:30 PM ET
Protalix Biotherapeutics Inc (PLX) Statistics
Protalix Biotherapeutics (PLX) has a market cap of $255.49M and an enterprise value of $233.45M. Revenue grew 36.96% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 8.62% below the market cap, as cash exceeds debt.
| Market Cap | $255.49M |
|---|---|
| Enterprise Value | $233.45M |
| Latest price (Nov 17, 2026) | $2.90 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.8x and 2.9x.
| P/E Ratio | 11.6x |
|---|---|
| Forward P/E | 11.9x |
| P/S Ratio | 2.8x |
| Forward P/S | 2.9x |
| P/B Ratio | 2.9x |
| P/FCF Ratio | 15.5x |
| P/OCF Ratio | 14.6x |
Enterprise Valuation
Counting debt and cash, the company is valued at 7.7x EBITDA and 14.0x free cash flow.
| EV / Earnings | 11.4x |
|---|---|
| EV / Sales | 2.8x |
| EV / EBITDA | 7.7x |
| EV / EBIT | 9.0x |
| EV / FCF | 14.0x |
Price Statistics
The stock is up 55.65% over 52 weeks and trades 7.41% above its 50-day average.
| Beta (1Y) | 1.06 |
|---|---|
| 52-Week Change | +55.65% |
| 1-Month Change | +13.09% |
| 3-Month Change | +23.19% |
| 6-Month Change | +52.37% |
| 5-Year Change | +129.20% |
| 10-Year Change | -44.91% |
| Total Return (1Y) | +55.65% |
| Total Return (3Y CAGR) | +27.39% |
| Return vs SPY (1Y) | +42.43% |
| Max Drawdown (1Y) | -39.68% |
| Max Drawdown (3Y) | -56.03% |
| Sharpe Ratio (1Y) | 0.78 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $2.70 |
| 200-Day Average | $2.45 |
| 52-Week Range | $1.65 to $3.19 |
| RSI (14 Days) | 56.5 |
| Average Volume (20 Days) | 984.45K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.27x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.27x |
|---|---|
| Quick Ratio | 2.14x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 25.51% and return on assets is 17.38% over the last 12 months.
| Return on Equity (ROE) | 25.51% |
|---|---|
| Return on Assets (ROA) | 17.38% |
| Return on Capital Employed (ROCE) | 29.37% |
| ROA (5Y Average) | -11.68% |
| ROIC (5Y Average) | -46.11% |
| Asset Turnover | 0.84x |
| Inventory Turnover | 0.73x |
| Receivables Turnover | 5.57x |
| Cash Conversion Cycle | 479 days |
Taxes
Income tax took 20.49% of pretax income over the last 12 months.
| Income Tax (TTM) | $5.30M |
|---|---|
| Effective Tax Rate | 20.49% |
Scores
PLX has an Altman Z-Score of 5.84, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.84 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $84.69M over the last 12 months.
| Revenue | $84.69M |
|---|---|
| Revenue Growth (YoY) | +36.96% |
| Gross Profit | $60.31M |
| Operating Income | $25.21M |
| Pretax Income | $25.85M |
| Net Income | $20.55M |
| EBITDA | $27.46M |
| EBIT | $25.85M |
| Reported EPS (TTM) | $0.25 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 68.12% of the $118.24M in total assets.
| Cash and Equivalents | $22.04M |
|---|---|
| Total Debt | $0 |
| Net Cash | $22.04M |
| Net Cash Per Share | $0.27 |
| Working Capital | $68.64M |
| Shareholder Equity | $80.55M |
| Book Value Per Share | $1.00 |
| Total Assets | $118.24M |
| Total Liabilities | $37.69M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.49M of capital spending, operating cash flow left $15.06M of free cash flow.
| Operating Cash Flow | $17.56M |
|---|---|
| Capital Expenditures | $2.49M |
| Free Cash Flow | $15.06M |
| FCF Per Share | $0.19 |
| Depreciation and Amortization | $1.62M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 29.76%, against a 5-year average of -13.56%.
| Gross Margin | 71.21% |
|---|---|
| Operating Margin | 29.76% |
| Pretax Margin | 30.52% |
| Net Margin | 24.27% |
| EBITDA Margin | 32.43% |
| EBIT Margin | 30.52% |
| FCF Margin | 17.79% |
| Gross Margin (5Y Average) | 56.89% |
| Operating Margin (5Y Average) | -13.56% |
| Net Margin (5Y Average) | -19.52% |
Growth
Revenue grew 3.45% a year over 3 years.
| Revenue Growth (3Y CAGR) | +3.45% |
|---|---|
| Revenue Growth (5Y CAGR) | -3.46% |
| Book Value Per Share Growth (2Y CAGR) | +15.52% |
| Tangible Book Per Share Growth (2Y CAGR) | +15.52% |
Dividends and Yields
PLX does not pay a dividend. Its free cash flow yield is 6.47%.
| Earnings Yield | 8.62% |
|---|---|
| FCF Yield | 6.47% |
| Buyback Yield | -1.81% |
| Shareholder Yield | -1.81% |
Stock Splits
The last split was a 1-for-10 reverse split on Dec 20, 2019.
| Last Split Date | Dec 20, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 8 similar companies, PLX has the 7th highest P/S.
P/S RatioPeer median 7.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +57.40%
| P/S Ratio | 2.8x vs 7.5x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +36.95% vs +57.40% median |
Analyst Forecast
Consensus estimates put revenue growth at 20.26% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +20.26% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PLX
What is PLX's market cap?
Protalix Biotherapeutics has a market cap of $255.49M. Its enterprise value, which adds debt and subtracts cash, is $233.45M.
What is PLX's P/E ratio?
Protalix Biotherapeutics has a trailing P/E ratio of 11.6x and a forward P/E of 11.9x.
How many shares of PLX are outstanding?
Protalix Biotherapeutics has 80.46M shares outstanding. The count is up 1.48% from a year earlier.
Does PLX pay a dividend?
No. Protalix Biotherapeutics does not pay a dividend.
How much debt does PLX have?
Protalix Biotherapeutics has $0 of total debt and $22.04M of cash and equivalents, a net cash position of $22.04M.
PLX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors